CD40 and hematopoietic and lymphoid cell neoplasm: Similarly, in hematological cancer (B cell NHL), CD40 engagement via dacetuzumab (humanised agonistic CD40 IgG1 mAb; alias: SGN-40) was tolerated well amongst patients.